Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia

Sanofi announced that its drug Wayrilz (rilzabrutinib), a BTK inhibitor, has received marketing authorization in Japan for treating persistent or chronic immune thrombocytopenia (ITP) in patients who don't respond to other treatments. The approval is based on the LUNA 3 phase 3 study, which demonstrated rapid and durable platelet response and improved quality of life compared to placebo.

06/23/2026, 1:15 AM • GlobeNewswire

Communiqué de presse : Wayrilz de Sanofi a été approuvé au Japon pour traiter la thrombocytopénie immunitaire

Sanofi announced that Wayrilz (rilzabrutinib), a BTK inhibitor, has received regulatory approval in Japan for treating persistent or chronic immune thrombocytopenia (ITP) in patients who are inadequately responsive to other treatments. The approval is based on the Phase 3 LUNA 3 trial, which demonstrated rapid and sustained platelet response and improved quality of life metrics. Wayrilz is now approved in the US, EU, UAE, UK, and Japan.

06/23/2026, 1:15 AM • GlobeNewswire

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

The European Commission has approved Sanofi's Cenrifki (tolebrutinib) for treating secondary progressive multiple sclerosis without relapses, marking the first disability-targeting therapy for this condition. The approval is based on the HERCULES phase 3 study demonstrating significant delay in disability progression. However, the drug carries identified safety risks including drug-induced liver injury, requiring strict liver monitoring.

06/23/2026, 1:00 AM • GlobeNewswire

Communiqué de presse : Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes

The European Commission has approved Sanofi's Cenrifki (tolebrutinib), a brain-penetrating Bruton tyrosine kinase inhibitor, for treating secondary progressive multiple sclerosis (SPMS) without relapses. The approval is based on the Phase 3 HERCULES trial, which demonstrated that Cenrifki significantly delayed disability progression. The drug will be commercially available in Germany this year, with careful risk management protocols due to identified hepatic safety concerns.

06/23/2026, 1:00 AM • GlobeNewswire

Communiqué de presse : Sarclisa de Sanofi en formulation sous-cutanée approuvé au Japon pour les patients atteints de myélome multiple

Sanofi a obtenu l'approbation au Japon pour Sarclisa en formulation sous-cutanée (SC) pour traiter le myélome multiple. Il s'agit de la deuxième approbation mondiale après l'UE. L'étude pivot IRAKLIA a démontré l'efficacité non-inférieure de la formulation SC par rapport à la formulation intraveineuse, avec un taux de réponse objective de 71,1% et un profil de sécurité amélioré.

06/19/2026, 6:31 AM • GlobeNewswire

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi announced approval of Sarclisa (isatuximab) subcutaneous formulation in Japan for multiple myeloma treatment in combination with standard-of-care regimens. This is the second global approval following EU authorization. The approval is based on the IRAKLIA phase 3 study demonstrating non-inferior efficacy and pharmacokinetics compared to intravenous formulation, with significantly fewer infusion reactions (1.5% vs 25%).

06/19/2026, 6:31 AM • GlobeNewswire

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.

06/18/2026, 1:00 PM • GlobeNewswire

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients

The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the decline of endogenous insulin production in children ages 8 to 17 recently diagnosed with stage 3 type 1 diabetes. The approval was based on Phase 3 PROTECT study data showing Tzield significantly slowed the decline in C-peptide levels versus placebo. This expands the drug's use following an earlier April 2026 label expansion for stage 2 disease patients as young as 1 year old.

06/15/2026, 1:15 PM • Benzinga

Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

The osteoarthritis market is projected to grow at a 3% CAGR from 2026 to 2036, reaching USD 32.5 billion in 2025 across seven major markets. Growth is driven by an aging population, rising disease prevalence, and the launch of emerging therapies including LEVI-04, ZILOSUL, TissueGene-C, and AMZ001. Current treatment is dominated by opioids, but novel disease-modifying therapies and regenerative medicine approaches are expected to reshape the market landscape.

06/15/2026, 1:00 PM • GlobeNewswire

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec un diabète de type 1 au stade 3

The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8-17 recently diagnosed with stage 3 type 1 diabetes, marking the first disease-modifying therapy for this indication. The approval is based on the phase 3 PROTECT trial demonstrating significant slowing of C-peptide decline. A confirmatory phase 3 BETA-PRESERVE study is currently underway.

06/12/2026, 6:09 PM • GlobeNewswire

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8-17 years recently diagnosed with stage 3 type 1 diabetes, making it the first disease-modifying therapy for this indication. The approval is based on the PROTECT phase 3 study showing significant slowing of C-peptide decline compared to placebo. A confirmatory BETA-PRESERVE study is ongoing.

06/12/2026, 6:09 PM • GlobeNewswire

Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses

Recludix Pharma announced preclinical data for REX-8756, an oral STAT6 inhibitor, demonstrating efficacy comparable to anti-IL-4/IL-13 antibody therapies in asthma and dermatitis models with a differentiated safety profile. The compound will be presented at EAACI and RAD congresses in June 2026. REX-8756 is currently in Phase 1 clinical trials under a partnership with Sanofi.

06/12/2026, 8:00 AM • GlobeNewswire

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Sanofi discontinued its Phase 3 MOBILIZE study of riliprubart for CIDP patients due to failure to meet efficacy objectives. The setback highlights trial design challenges in CIDP studies and may strengthen Argenx's Vyvgart market position, which has demonstrated successful trial execution in the same indication.

06/11/2026, 9:09 AM • Benzinga

HR Tech 2026 Announces Initial Agenda: Focuses on Real-World AI Implementation, Skills, and Workforce Transformations

HR Tech 2026 conference (October 20-22 in Las Vegas) unveiled its agenda featuring sessions on AI implementation, skills development, and workforce transformation. Leading HR and talent executives from major companies including Amsted Industries, Cloudflare, IFF, Lumen, Sanofi, and TIAA will share practical strategies on job architecture, AI adoption, internal mobility, and HR technology readiness.

06/09/2026, 7:00 AM • GlobeNewswire